BioSpace News Archive

Afya Limited, or Afya, in light of the recent developments of the Coronavirus pandemic, informs shareholders and the market of the measures the company is taking to mitigate any potential impact to students and employees.

HTG Molecular Diagnostics, Inc. announced that it will report its financial results for the year ended December 31, 2019 after the market close on Wednesday March 25, 2020.

Morphic Therapeutic today announced the appointment of Peter G. Linde, M.D., as chief medical officer. Dr. Linde was previously vice president of medical research at Acceleron Pharma, Inc., where he was responsible for the design and execution of clinical trials with positive outcomes in both pulmona

Surface Oncology today announced that it has initiated a Phase 1/1b clinical trial of its antibody candidate SRF617, which targets the immunosuppressive protein CD39. “Our comprehensive preclinical data indicate SRF617 is a potent inhibitor of CD39, which may play an important role in tumor growth

Eton Pharmaceuticals, Inc today announced positive bioequivalence study results for ET-101, its proprietary oral solution formulation of topiramate. A bioequivalen

Fulgent Genetics will partner with MedScan Laboratory to launch one of the market’s first COVID-19 tests based on comprehensive Next Generation Sequencing technology

Global Blood Therapeutics, Inc. announced steps the company is taking to support public health efforts to address the COVID-19 pandemic.

New coronavirus test may be able to confirm COVID-19 in under one hour at the point of care

Health Catalyst, Inc. announced that, after dozens of conversations with health system clients, the company will initially be offering three COVID-19 Solutions to its domestic clients, with the first of these solutions becoming available to pilot clients by the end of March.

Lattice Biologics Ltd. ( TSX-V: LBL ) (OTCBB: LBLTF) (“Lattice Biologics” or the “Company”) announces it has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its novel stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection. AmnioBoost is derived from amniotic fluid taken from non-related, healthy, living